Publications by authors named "J P Pidlich"
Medical care for psychosomatic patients in Austria differs from Germany. Besides treatment in psychiatric wards, there are also inpatient programs for psychosomatic patients integrated in internal medical departments. Such an integrated ward in Lower Austria operates for more than 35 years and treats internal-psychosomatic and gastroenterological patients.
View Article and Find Full Text PDFTransjugular intrahepatic portosystemic shunt in Vienna--a decade later.
Wien Klin Wochenschr
September 2004
Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) for therapy of portal hypertension has been available in Vienna, Austria, since 1991. Ten years of experience with this technique led the Vienna TIPS Study Group to retrospectively analyse characteristics and outcome of all patients undergoing TIPS in Vienna between 1991 and 2001. Survival and subgroup analyses were performed using Mann Whitney U-tests, log-rank tests, Spearman's correlation and Kaplan-Meier analyses.
View Article and Find Full Text PDFBackground: In patients undergoing transjugular intrahepatic portosystemic shunt (TIPS), prognostic scores may identify those with a poor prognosis or even those with a clear survival benefit. The Child-Pugh score (CPS) is well established but several drawbacks have led to development of the model of end stage liver disease (MELD).
Aim: The aim of the study was to compare the predictive power of CPS and MELD, to validate the original MELD formula, and to assess the predictive value of the determinants used in the two prognostic scores outside of a study setting.
Article Synopsis
- The study tested if cognitive brain dysfunction in cirrhotic patients worsens after receiving a transjugular intrahepatic portosystemic shunt (TIPS), even without visible hepatic encephalopathy.
- Before and 6 months after TIPS, patients showed significant cognitive impairments compared to healthy controls, with a noted decline in cognitive processing speed post-TIPS.
- The results suggest that even in the absence of clear symptoms, patients with portal hypertension experience further cognitive decline after the procedure, indicating worsening subclinical hepatic encephalopathy.
Background: A multicenter phase II trial was initiated to investigate the efficacy and tolerance of a dose-fractionated administration schedule of irinotecan in patients with advanced colorectal cancer pre-treated with fluoropyrimidine/ oxaliplatin-based first-line combination chemotherapy.
Patients And Methods: 38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study. Treatment consisted of irinotecan 175 mg/m2 given on days 1 and 10.